CTI Clinical Trial and Consulting Services Announces Acquisition of CRS Clinical Research Services
Cincinnati, Ohio
CTI Clinical Trial and Consulting Services (CTI) announces the acquisition of CRS Clinical Research Services and CRS – Staff Leasing Services (CRS), a clinical research organization headquartered in Northern Germany. CTI will incorporate all CRS employees into its current European operations and maintain the CRS headquarters located near Hamburg, Germany. CTI is planning to augment its coverage in Germany with the opening of an additional office in the southern region of the country in the coming months.
CRS is a full service, therapeutically-focused clinical research organization, with an emphasis on phase II and phase III clinical trials. Therapeutic areas of focus include infectious disease, oncology, and autoimmune diseases. CRS has managed clinical trials for large pharmaceutical companies, biotechnology companies, and for non-profit organizations across Western Europe.
“The addition of the CRS management and research teams will significantly advance CTI’s current expansion in Europe,” says Timothy Schroeder, CTI President and CEO.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
